Evidence map›Paper›PMID 38846562›Full record

ArticleFrontiers in microbiology2024

Hypervirulent

Likhona Dingiswayo, Olusesan Adeyemi Adelabu, Emmanuel Arko-Cobbah, Carolina Pohl, Nthabiseng Zelda Mokoena, Morne Du Plessis, Jolly Musoke

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Genomic characterisation and antimicrobial resistance ofFrontiers in cellular and infection microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Likhona DingiswayoDepartment of Medical Microbiology, School of Pathology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
Olusesan Adeyemi AdelabuDepartment of Medical Microbiology, School of Pathology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
Emmanuel Arko-CobbahDepartment of Surgery, School of Clinical Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
Carolina PohlDepartment of Microbiology and Biochemistry, Faculty of Natural and Agricultural Sciences, University of the Free State, Bloemfontein, South Africa.
Nthabiseng Zelda MokoenaDepartment of Microbiology and Biochemistry, Faculty of Natural and Agricultural Sciences, University of the Free State, Bloemfontein, South Africa.
Morne Du PlessisDepartment of Genetics, Faculty of Natural and Agricultural Sciences, University of the Free State, Bloemfontein, South Africa.
Jolly MusokeDepartment of Medical Microbiology, School of Pathology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.

Funding

Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Ann E. Rougvie · 2012 to 2026
$7.5M
NIH HHS P40 OD010440
6 · The paper itself

Abstract

Introduction: A distinct strain of Methods: A total of 74 Results: Nine (12.2%) isolates were identified as hvKp. Moreover, hvKp was significantly ( Conclusion: Findings from this study confirm the presence of hvKp in a large tertiary hospital in central South Africa. However, the low prevalence and mild to moderate clinical presentation of infected patients suggest a marginal threat to public health. Further studies in different settings are required to establish the true potential impact of hvKp in developing countries.

Indexed as

aerobactinCaenorhabditis eleganscapsulehypervirulentKlebsiella pneumoniaeserotypevirulence

Identifiers

PMID38846562
PMCPMC11156222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.